| Market Cap | 252.34B | P/E | 17.22 | EPS this Y | 7.40% | Ern Qtrly Grth | -12.30% |
| Income | 10.62B | Forward P/E | 14.36 | EPS next Y | 9.20% | 50D Avg Chg | -1.00% |
| Sales | 60.58B | PEG | 1.82 | EPS past 5Y | -1.28% | 200D Avg Chg | -1.00% |
| Dividend | 3.00% | Price/Book | 8.82 | EPS next 5Y | 6.62% | 52W High Chg | -12.00% |
| Recommedations | 4.00 | Quick Ratio | 0.80 | Shares Outstanding | 690.10M | 52W Low Chg | 13.00% |
| Insider Own | - | ROA | 12.49% | Shares Float | 726.97M | Beta | 0.15 |
| Inst Own | 38.31% | ROE | 36.36% | Shares Shorted/Prior | -/- | Price | 308.83 |
| Gross Margin | 74.54% | Profit Margin | 17.53% | Avg. Volume | 8,359 | Target Price | - |
| Oper. Margin | 35.27% | Earnings Date | Jul 25 | Volume | 13,680 | Change | 1.32% |
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.